Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study
2008 ◽
Vol 26
(15_suppl)
◽
pp. 16027-16027
2005 ◽
Vol 23
(16_suppl)
◽
pp. 4613-4613
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 16019-16019
◽